peer reviewedOver recent years, anti-TNFalpha have been used to treat rheumatoid arthritis. The principal secondary effect of anti-TNFalpha is tuberculosis infections. Another paradoxical effect, previously less well understood, is the development of sarcoid-like granulomatous reactions. We report the case of a 36 year old woman who had been treated for 9 years with anti-TNF alpha. She developed a pulmonary sarcoid-like gra-nulomatosis, complication that is rare but not exceptional in patients treated with TNF-blockers. Discontinuation of anti TNF usually led to recovery. It has been suggested that these reactions mainly occur with etanercept, but this requires further confirmation
International audienceIntroductionThe principal secondary effects of anti-TNF alpha therapy are now ...
Summary We report the case of a patient with rheumatoid arthritis who, after 2 months of treatment w...
Anti-tumor necrosis factor alpha (anti-TNF-a) therapy has been widely used for the management of rhe...
International audienceOBJECTIVE: TNF blockers have been recently evaluated for treating refractory s...
International audienceINTRODUCTION: TNF blockers are widely used to treat inflammatory rheumatic dis...
International audienceAnti-TNF-alpha agents have been tried in cases of refractory sarcoidosis, givi...
Etanercept is a soluble receptor fusion protein that inhibits tumor necrosis factor-alpha(TNF-&alpha...
Etanercept is a soluble receptor fusion protein that inhibits tumor necrosis factor-alpha(TNF-&alpha...
Objectives: to report 2 cases of sarcoidosis developed during treatment with anti-TNFalfa antagonist...
AbstractSarcoidosis is a multisystem granulomatous inflammatory disease of unknown etiology. There i...
Paradoxical effects or reactions to anti–tumor necrosis factor (anti-TNF) therapy are defined by the...
Drug-induced sarcoidosis-like disease is a rare side effect of anti-tumor necrosis factor (anti-TNF)...
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the ...
We report a 55-year-old female with seropositive rheumatoid arthritis for 10 years who developed lar...
Sarcoidosis is a systemic chronic granulomatous disease of unknown etiology. It predominantly involv...
International audienceIntroductionThe principal secondary effects of anti-TNF alpha therapy are now ...
Summary We report the case of a patient with rheumatoid arthritis who, after 2 months of treatment w...
Anti-tumor necrosis factor alpha (anti-TNF-a) therapy has been widely used for the management of rhe...
International audienceOBJECTIVE: TNF blockers have been recently evaluated for treating refractory s...
International audienceINTRODUCTION: TNF blockers are widely used to treat inflammatory rheumatic dis...
International audienceAnti-TNF-alpha agents have been tried in cases of refractory sarcoidosis, givi...
Etanercept is a soluble receptor fusion protein that inhibits tumor necrosis factor-alpha(TNF-&alpha...
Etanercept is a soluble receptor fusion protein that inhibits tumor necrosis factor-alpha(TNF-&alpha...
Objectives: to report 2 cases of sarcoidosis developed during treatment with anti-TNFalfa antagonist...
AbstractSarcoidosis is a multisystem granulomatous inflammatory disease of unknown etiology. There i...
Paradoxical effects or reactions to anti–tumor necrosis factor (anti-TNF) therapy are defined by the...
Drug-induced sarcoidosis-like disease is a rare side effect of anti-tumor necrosis factor (anti-TNF)...
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the ...
We report a 55-year-old female with seropositive rheumatoid arthritis for 10 years who developed lar...
Sarcoidosis is a systemic chronic granulomatous disease of unknown etiology. It predominantly involv...
International audienceIntroductionThe principal secondary effects of anti-TNF alpha therapy are now ...
Summary We report the case of a patient with rheumatoid arthritis who, after 2 months of treatment w...
Anti-tumor necrosis factor alpha (anti-TNF-a) therapy has been widely used for the management of rhe...